- Home
- NVCT vs RAPT Comparison
NVCT vs RAPT Comparison
Compare NVCT & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVCT
- RAPT
- Stock Information
- Founded
- NVCT 2020
- RAPT 2015
- Country
- NVCT United States
- RAPT United States
- Employees
- NVCT N/A
- RAPT N/A
- Industry
- NVCT Medicinal Chemicals and Botanical Products
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- NVCT Health Care
- RAPT Health Care
- Exchange
- NVCT Nasdaq
- RAPT Nasdaq
- Market Cap
- NVCT 167.0M
- RAPT 194.2M
- IPO Year
- NVCT 2022
- RAPT 2019
- Fundamental
- Price
- NVCT $6.40
- RAPT $13.28
- Analyst Decision
- NVCT Strong Buy
- RAPT Buy
- Analyst Count
- NVCT 3
- RAPT 5
- Target Price
- NVCT $15.33
- RAPT $33.60
- AVG Volume (30 Days)
- NVCT 75.1K
- RAPT 117.5K
- Earning Date
- NVCT 11-04-2025
- RAPT 08-07-2025
- Dividend Yield
- NVCT N/A
- RAPT N/A
- EPS Growth
- NVCT N/A
- RAPT N/A
- EPS
- NVCT N/A
- RAPT N/A
- Revenue
- NVCT N/A
- RAPT N/A
- Revenue This Year
- NVCT N/A
- RAPT N/A
- Revenue Next Year
- NVCT N/A
- RAPT N/A
- P/E Ratio
- NVCT N/A
- RAPT N/A
- Revenue Growth
- NVCT N/A
- RAPT N/A
- 52 Week Low
- NVCT $4.44
- RAPT $5.67
- 52 Week High
- NVCT $11.80
- RAPT $26.56
- Technical
- Relative Strength Index (RSI)
- NVCT 44.54
- RAPT 64.67
- Support Level
- NVCT $6.32
- RAPT $11.19
- Resistance Level
- NVCT $6.90
- RAPT $13.66
- Average True Range (ATR)
- NVCT 0.34
- RAPT 0.82
- MACD
- NVCT 0.05
- RAPT 0.18
- Stochastic Oscillator
- NVCT 36.71
- RAPT 89.44
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.